Pharma Trek Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 26 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.91 Cr
as on 12-12-2024
- Satisfied Charges ₹ 4.41 Cr
as on 12-12-2024
- Revenue 6.99%
(FY 2022)
- Profit 17.10%
(FY 2022)
- Ebitda 35.09%
(FY 2022)
- Net Worth 10.75%
(FY 2022)
- Total Assets -13.30%
(FY 2022)
About Pharma Trek
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.91 Cr. The company has closed loans amounting to ₹4.41 Cr, as per Ministry of Corporate Affairs (MCA) records.
Prakash Abhilash and Ethnur Padmaja serve as directors at the Company.
- CIN/LLPIN
U51102TN1998PTC041013
- Company No.
041013
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Aug 1998
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Pharma Trek?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prakash Abhilash  | Director | 18-Jun-2007 | Current |
| Ethnur Padmaja | Director | 20-Aug-1998 | Current |
Financial Performance of Pharma Trek.
Pharma Trek Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 6.99% increase. The company also saw a substantial improvement in profitability, with a 17.1% increase in profit. The company's net worth Soared by an impressive increase of 10.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharma Trek?
In 2022, Pharma Trek had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Vaxidrug Pharmaceuticals Private LimitedActive 10 years 3 months
Prakash Abhilash is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Jan 2022 | ₹2.91 Cr | Open |
Others Creation Date: 24 Jan 2019 | ₹2.66 Cr | Satisfied |
Others Creation Date: 23 Feb 2017 | ₹1.75 Cr | Satisfied |
How Many Employees Work at Pharma Trek?
Unlock and access historical data on people associated with Pharma Trek, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharma Trek, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharma Trek's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
